Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Hyper-CVAD in Relapsed/Refractory ALL
NCT00968253Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2009
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2009; status: completed.
02
Drugs
everolimus
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00968253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00968253.